Table 1.
Demographic data of the placebo and galantamine-treated groups at baseline.
| Placebo group (n = 6) | Galantamine group (n = 12) | Total (n = 18) | |
|---|---|---|---|
| Gender (F/M) | 3/3 | 5/7 | 8/10 |
| Average age in | 65.8 ± 3.7 | 70.9 ± 2.7 | 69.2 ± 2.2 |
| years (range) | |||
| ApoE 4 carriers (+/−) | 3/2 | 7/3 | 10/5 |
| Duration of disease (years) | 2.2 ± 0.7 | 5.1 ± 1.1 | 4.1 ± 0.8 |
| Education, mean years (range) | 12.8 ± 0.9 | 10.9 ± 1.1 | 11.4 ± 0.9 |
| ADAS-cog | 19.0 ± 1.1 | 28.0 ± 3.4 | 26.2 ± 0.7 |
| MMSE | 27.3 ± 0.8 | 25.6 ± 1.0 | 26.2 ± 0.7 |
Values correspond to mean ± SEM. F, females and M, males. MMSE, Mini-Mental State Examination. ADAS-cog/13, Alzheimer’s Disease Assessment Scale-cognitive subscale. Although the placebo randomized patients appear younger, having shorter duration of the disease, higher MMSE scores and lower ADAS-cog scores at baseline compared with the galantamine group, no statistical significant difference was observed with regards to age, gender, level of education, duration of disease, MMSE and ADAS-cog scores at baseline (all p > 0.10 except for ADAS-cog, p = 0.09; Kadir et al., 2008).